

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ascletis Pharma Inc.**  
**歌禮製藥有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1672)**

**RESIGNATION OF NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of Ascletis Pharma Inc. (the “**Company**”) announces that it received a letter of resignation from Mr. Wei FU (“**Mr. Fu**”) on December 24, 2018 resigning his position as a non-executive Director with effect from December 24, 2018. Mr. Fu resigned from the Board due to his other business engagements requiring more of his time and dedication which may affect his time commitment to the Company.

Mr. Fu has confirmed that he has no disagreement with the Board and there are no other matters with respect to his resignation that need to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited.

The Board would like to take this opportunity to thank Mr. Fu for his efforts and valuable contributions to the Company during his tenure of office.

By Order of the Board  
**Ascletis Pharma Inc.**  
歌禮製藥有限公司  
**Jinzi Jason WU**  
*Chairman*

Hangzhou, the People’s Republic of China  
December 24, 2018

*As at the date of this announcement, the Board comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Ru Rong JI, Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.*